Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 6:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 124 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Esomeprazole Clear all
Terminated Phase 4 Interventional

Metformin and Esomeprazole in Preterm Pre-eclampsia

NCT06359015
View directory record Official record
Conditions
Preeclampsia Severe, Pre-Eclampsia, Preeclampsia, Preeclampsia Second Trimester, Preeclampsia Complicating Childbirth, Preeclampsia Puerperium, Preterm
Interventions
Metformin, Esomeprazole
Drug
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Sep 1, 2026, 6:55 PM EDT
Completed Phase 4 Interventional

An Open Label pH Comparison of Esomeprazole and Lansoprazole in Barrett's Esophagus Patients

NCT00352261
View directory record Official record
Conditions
Barrett's Esophagus
Interventions
Esomeprazole, Lansoprazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
12
States / cities
Phoenix, Arizona • Tucson, Arizona • North Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2009 · Synced Sep 1, 2026, 6:55 PM EDT
Completed Phase 3 Interventional Results available

Phase 3/Safety & Efficacy of Esomeprazole in Infants

NCT00468559
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Open Label Run In Esomeprazole, Double Blind Esomeprazole, Double Blind Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
1 Month to 11 Months
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
14
States / cities
Phoenix, Arizona • Atlanta, Georgia • Park Ridge, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2014 · Synced Sep 1, 2026, 6:55 PM EDT
Completed Not applicable Interventional Results available

Ablation of Intestinal Metaplasia Containing Dysplasia

NCT00282672
View directory record Official record
Conditions
Barrett Esophagus
Interventions
Ablation System plus anti-secretory medication, Sham procedure plus anti-secretory medication
Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
18 Years to 80 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
19
States / cities
Scottsdale, Arizona • Tucson, Arizona • Orange, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Sep 1, 2026, 6:55 PM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis

NCT00664560
View directory record Official record
Conditions
Osteoarthritis
Interventions
PN 400 (VIMOVO), celebrex, Placebo, Rescue Antacid
Drug
Lead sponsor
POZEN
Industry
Eligibility
50 Years and older
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 26, 2012 · Synced Sep 1, 2026, 6:55 PM EDT
Completed Phase 3 Interventional

Safety of Daily Dose Esomeprazole for GERD for Pediatric and Adolescent Patients

NCT00241501
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Esomeprazole (Nexium)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 17 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
28
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Wilmington, Delaware + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2010 · Synced Sep 1, 2026, 6:55 PM EDT
Completed Phase 4 Interventional

An Open-label, Exploratory Trial to Assess Gastric Acid Control in Critically Ill Subjects Receiving Nexium

NCT00428701
View directory record Official record
Conditions
Gastric Ulcer
Interventions
Esomeprazole Sodium
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
5
States / cities
Newark, Delaware • Shreveport, Louisiana • Hershey, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2011 · Synced Sep 1, 2026, 6:55 PM EDT
Completed Phase 3 Interventional

Esomeprazole for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs

NCT00241527
View directory record Official record
Conditions
NSAIDs, Upper GI Symptoms
Interventions
Esomeprazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
556 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
32
States / cities
Tallassee, Alabama • Phoenix, Arizona • Garden Grove, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2011 · Synced Sep 1, 2026, 6:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil

NCT00963027
View directory record Official record
Conditions
Hypertension, Pulmonary, Pulmonary Arterial Hypertension
Interventions
Treprostinil diethanolamine, Esomeprazole
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 7, 2010 · Synced Sep 1, 2026, 6:55 PM EDT
Terminated Phase 1 Interventional

Effect of Acid Reflux on Respiratory Physiology During Exercise in Athletes With GER-Response to Acid Suppression

NCT00444236
View directory record Official record
Conditions
Exercise Triggered Asthma, Gastroesophageal Reflux
Interventions
Nexium, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Sep 1, 2026, 6:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assess the Drug Interactions of BBT-877 and Midazolam, Itraconazole, and Esomeprazole in Healthy Adult Subjects

NCT04138836
View directory record Official record
Conditions
Healthy Participants
Interventions
BBT-877, Midazolam, Itraconazole, Esomeprazole
Drug
Lead sponsor
Bridge Biotherapeutics, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 1, 2026, 6:55 PM EDT
Completed Phase 4 Interventional Results available

VEG113971: An Open-Label Study of the Effects of Ketoconazole or Esomeprazole on Pazopanib PK

NCT01205230
View directory record Official record
Conditions
Cancer
Interventions
pazopanib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
New Brunswick, New Jersey • Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated May 21, 2012 · Synced Sep 1, 2026, 6:55 PM EDT
Completed Phase 2 Interventional

The Safety and Efficacy of Dexloxiglumide for the Relief of Symptoms of Functional Dyspepsia.

NCT00303264
View directory record Official record
Conditions
Dyspepsia
Interventions
dexloxiglumide, Nexium (esomeprazole)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 4, 2012 · Synced Sep 1, 2026, 6:55 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Comparison of Voice Therapy and Antireflex Therapy in LPR

NCT02530879
View directory record Official record
Conditions
Laryngopharyngeal Reflux
Interventions
Omeprazole, Lansoprazole, Esomeprazole, Rantidine, Voice therapy, Combination of anti-reflux medication and voice therapy
Drug · Behavioral · Other
Lead sponsor
Temple University
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Sep 1, 2026, 6:55 PM EDT
Completed Phase 3 Interventional Results available

Study of Esomeprazole 20 mg or 40 mg vs Placebo Effectiveness on the Occurrence of Peptic Ulcers in Subjects on Low Dose Acetylsalicylic Acid (LDA)

NCT00441727
View directory record Official record
Conditions
Gastric Ulcer, Duodenal Ulcer
Interventions
Esomeprazole 40 mg, Esomeprazole 20 mg, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
2,426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
55
States / cities
Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 52 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2012 · Synced Sep 1, 2026, 6:55 PM EDT
Completed Phase 4 Interventional

Esomeprazole for Treatment of GERD in Pediatric Patients

NCT00228527
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD), Erosive Esophagitis, Non-erosive Esophagitis
Interventions
Esomeprazole (Nexium)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
1 Year to 11 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
24
States / cities
Mobile, Alabama • Phoenix, Arizona • Wilmington, Delaware + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2010 · Synced Sep 1, 2026, 6:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect on 24-hour, Intragastric pH of RAB ER 50-mg Capsules Compared With Esomeprazole (Nexium) 40 mg Capsules and Rabeprazole (Aciphex) 20-mg Tablets

NCT01153659
View directory record Official record
Conditions
Healthy
Interventions
E3810, Aciphex (rabeprazole), Nexium (esomeprazole)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Oct 31, 2013 · Synced Sep 1, 2026, 6:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Potential Influence of Esomeprazole on the Pharmacokinetics of Pritelivir

NCT05513625
View directory record Official record
Conditions
HSV Infection
Interventions
Pritelivir, ESO and pritelivir
Drug
Lead sponsor
AiCuris Anti-infective Cures AG
Industry
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Sep 1, 2026, 6:55 PM EDT
Completed Phase 4 Interventional

An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD)

NCT00242736
View directory record Official record
Conditions
GERD
Interventions
Esomeprazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
25
States / cities
Alabaster, Alabama • Mobile, Alabama • Tucson, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2009 · Synced Sep 1, 2026, 6:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic (PK) Study Evaluating Naproxen and Esomeprazole Plasma Levels

NCT00749385
View directory record Official record
Conditions
Arthritis
Interventions
PN 400, EC naproxen plus EC esomeprazole, EC naproxen, EC esomeprazole
Drug
Lead sponsor
POZEN
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 22, 2008 · Synced Sep 1, 2026, 6:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Investigate the Effect of Esomeprazole and the Effect of Food on the Pharmacokinetics of Balovaptan in Healthy Volunteers

NCT04156646
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Balovaptan, Esomeprazole
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2021 · Synced Sep 1, 2026, 6:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Pharmacokinetics (PK) of Brensocatib Alone and With Multiple Doses of Rifampin or Esomeprozole in Healthy Participants

NCT05826574
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Brensocatib, Rifampin, Esomeprazole
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced Sep 1, 2026, 6:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants

NCT07018635
View directory record Official record
Conditions
Healthy Participants
Interventions
INCB161734, Itraconazole, Rifampin, Esomeprazole, Famotidine
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Sep 1, 2026, 6:55 PM EDT
Completed Phase 2 Interventional

A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients Without Erosive Esophagitis.

NCT00206284
View directory record Official record
Conditions
GERD Without Erosive Esophagitis
Interventions
AZD0865
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
77
States / cities
Alabaster, Alabama • Huntsville, Alabama • Tucson, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Sep 1, 2026, 6:55 PM EDT